NCT04655612View on ClinicalTrials.gov

Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases

CompletedOBSERVATIONAL

Enrollment

5,000

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

July 1, 2021

Study Completion Date

July 30, 2021

Conditions

COVID-19SARS-CoV InfectionRheumatoid ArthritisSpondyloarthritisAnkylosing SpondylitisPsoriatic Arthritis

Trial Locations (1)

34295

Centre hopsitalier universitaire de Montpellier, Montpellier

All Listed Sponsors

lead

University Hospital, Montpellier

OTHER

NCT04655612 - Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases | Biotech Hunter | Biotech Hunter